No evidence for BRAF-V600E mutations in gastroeosophageal tumors: Results from a high-throughput analysis of 534 cases using a mutation-specific antibody

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 5, 2013, Pages 426-430

  Preusser, Matthias ^a   Berghoff, Anna S ^a,b   Capper, David ^c,d   Von Deimling, Andreas ^c,d   Maroske, Florian ^a   Brodowicz, Thomas ^a   Hejna, Michael ^a   Birner, Peter ^a   Schoppmann, Sebastian F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

BRAF; BRAF V600E mutation; gastric gastrointestinal stromal tumors; gastroesophageal tumors; immunohistochemistry; upper gastrointestinal tract tumor; v raf murine sarcoma viral oncogene homolog B1

Indexed keywords

B RAF KINASE; FORMALDEHYDE; PARAFFIN;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS TUMOR; FEMALE; GASTROESOPHAGUS TUMOR; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS B-RAF; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84885086057     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31827ce693     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Wang J, Yu JC, Kang WM, et al. Treatment strategy for early gastric cancer. Surg Oncol. 2012;21:119-123.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
4. Almhanna K. Targeted therapy for gastric adenocarcinoma. Adv Pharmacol. 2012;65:437-470.
5. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855-867.
6. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
7. Edlundh-Rose E, Egyhazi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006;16:471-478.
8. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairycell leukemia. N Engl J Med. 2011;364:2305-2315.
9. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
10. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006;5:2-7.
11. Phipps AI, Buchanan DD, Makar KW, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2012;21:1792-1798.
12. Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11:873-886.
13. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1964-1703.
14. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2012. (In press).
15. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120:e28-e34.
16. Preusser M, Capper D, Berghoff AS, et al. Expression of BRAF V600E mutant protein in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol. 2012. (In press).
17. Capper D, Berghoff AS, von Deimling A, et al. Clinical neuropathology practice news 2-2012: BRAF V600E testing. Clin Neuropathol. 2012;31:64-66.
18. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223-233.
19. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
20. Birner P, Beer A, Vinatzer U, et al. MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1. Clin Cancer Res. 2012;18:1879-1887.
21. Schoppmann SF, Berghoff AS, Jesch B, et al. Expression of podoplanin is a rare event in sporadic gastrointestinal stromal tumors and does not influence prognosis. Future Oncol. 2012;8: 859-866.
22. Luber B, Deplazes J, Keller G, et al. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer. 2011;11:509-519.
23. Corso G, Velho S, Paredes J, et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer. 2011;47: 443-451.
24. Zhao W, Chan TL, Chu KM, et al. Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. Int J Cancer. 2004;108:167-169.
25. Wu M, Semba S, Oue N, et al. BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. Gastric Cancer. 2004;7:246-253.
26. Maeng CH, Lee J, van Hummelen P, et al. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3- kinase and BRAF mutations. PLoS One. 2012;7:e41655.
27. Lee SH, Lee JW, Soung YH, et al. BRAF and KRAS mutations in stomach cancer. Oncogene. 2003;22:6942-6945.
28. Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133: 141-148.
29. Pera M, Iglesias M, Puig S, et al. A sporadic multiple gastrointestinal stromal tumor with unique clinical and molecular features. Hum Pathol. 2011;42:1194-1199.
30. Agaimy A, Terracciano LM, Dirnhofer S, et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/ PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009;62:613-616.
31. Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47:853-859.
32. Daniels M, Lurkin I, Pauli R, et al. Spectrum of KIT/PDGFRA/ BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 2011;312:43-54.
33. Miettinen M, Wang ZF, Sarlomo-Rikala M, et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011;35:1712-1721.